Redeye provides an initial take following the release of Corline’s Q4 2025 report. Sales came in below our expectations, while costs were somewhat higher than anticipated. Although we were aware that this quarter would be challenging to forecast, we are surprised that clearer signs of a sales ramp-up linked to Kardium’s launch of the Globe system have yet to materialise. We will publish a research update in which we expect to adopt a more cautious stance for the coming quarters, with estimate revisions that could result in a slightly lower fair value range.
LÄS MER
